Annual General Meeting
Dr James Campbell, CEO 11 November 2015
This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Patrys Limited to be materially different from the statements in this presentation.
Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's patent protection.
Annual General Meeting
November 2015
ChallengesPAT-SM6 manufacturing difficulties
o Clinical trial deferral
CAR T cell program discontinued
DevelopmentsBoard of Directors unified in its commitment to rebuilding shareholder value
Appointed experienced CEO
Completed Chinese licensing deal for clinical candidate PAT-SC1
Completed corporate restructuring - strong cash position
Completing transformation
Annual General Meeting
November 2015
John Read
James Campbell Mike Stork
Suzy Jones Melanie Leydin Deanne Greenwood
Valentina Dubljevic
Chairman
CEO & Managing Director Non-Executive Director Non-Executive Director CFO & Company Secretary
VP, Business Development & IP
VP, Scientific & Clinical Development
International clinical and business development expertise
Substantial expertise in antibody development
Experienced in corporate financings, licensing and M&A transactions
Extensive big biotech & pharma contacts
Annual General Meeting
November 2015
distributed by |